A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

NCT01730248 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

63

Enrollment

INDUSTRY

Sponsor class

Stopped Decision by Sponsor to to terminate the study early.

Conditions

Myelofibrosis

Interventions

DRUG: INC424
DRUG: BKM120

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]